Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Prediction of Smoking Cessation Medication Side Effects: A Genome-Wide Investigation of Abnormal Dreams on Varenicline.

Clinical pharmacology and therapeutics - 1 Jun 2024

Chenoweth Meghan J, Kim Yong Jae, Nollen Nikki L, Hawk Larry W, Mahoney Martin C, Lerman Caryn, Knight Jo, Tyndale Rachel F

Abstract excerpt

Varenicline, the most efficacious smoking cessation monotherapy, produces abnormal dreams. Although genetic contributions to varenicline-associated nausea and cessation have been identified, the role of genetics in abnormal dreams is unknown. We conducted a genomewide association study (GWAS) of abnormal dreams in 188 European ancestry smokers treated with varenicline (NCT01314001). Additive genetic models...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genome-Wide Association Study
Share to Polymorphism, Single Nucleotide

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Smoking Cessation

Source

Open in PubMed Open full text

Identifiers

PMID: 38369951
DOI: 10.1002/cpt.3210
PMCID: PMC13035048

Genes

ICAM5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Prediction of Smoking Cessation Medication Side Effects: A Genome-Wide Investigation of Abnormal Dreams on Varenicline.PMID 38369951Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.Semantic proximity Read ↗

Studies towards stratified approaches to smoking cessation with a focus on South Asians and effectiveness of vareniclineSemantic proximity Read ↗

Prediction of antidepressant side effects in the Genetic Link to Anxiety and Depression StudySemantic proximity Read ↗

Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genesSemantic proximity Read ↗

Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood.Semantic proximity Read ↗

Gene-based association analysis reveals involvement of LAMA5 and cell adhesion pathways in nicotine dependence in African- and European-American samples.Semantic proximity Read ↗

Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.Semantic proximity Read ↗

Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 ReportSemantic proximity Read ↗

A novel smoking cessation behavior based on quit attempts may identify new genes associated with long-term abstinence.Semantic proximity Read ↗

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Semantic proximity Read ↗

The clinical usefulness of knowing CHRNA5 polymorphism genotype: paving the way for personalized therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.